N
44.56
-2.43 (-5.17%)
| Previous Close | 46.99 |
| Volume | 1,472,286 |
| Price / Sales | 25.68 |
| Price / Book | 2.18 |
| 52 Weeks Range |
| Profit Margin | -152.49% |
| Operating Margin (TTM) | -424.15% |
| Diluted EPS (TTM) | -9.45 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Total Debt/Equity (MRQ) | 1,358.71% |
| Current Ratio (MRQ) | 3.24 |
| Operating Cash Flow (TTM) | -176.87 M |
| Levered Free Cash Flow (TTM) | -47.84 M |
| Return on Assets (TTM) | -26.80% |
| Return on Equity (TTM) | -189.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Nektar Therapeutics | Mixed | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 67.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Two Seas Capital Lp | 30 Jun 2026 | 3,092,234 |
| Prosight Management, Lp | 30 Jun 2026 | 810,000 |
| Armistice Capital, Llc | 30 Jun 2026 | 724,000 |
| Gilder Gagnon Howe & Co Llc | 30 Jun 2026 | 600,873 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AJER JEFFREY ROBERT | 57.66 | - | 2,000 | 115,320 |
| BRAINARD DIANA | 57.66 | - | 2,000 | 115,320 |
| CHESS ROBERT | 57.66 | - | 2,000 | 115,320 |
| GREER R SCOTT | 57.66 | - | 2,000 | 115,320 |
| WHITFIELD ROY A | 57.66 | - | 2,000 | 115,320 |
| Aggregate Net Quantity | 10,000 | |||
| Aggregate Net Value ($) | 576,600 | |||
| Aggregate Avg. Buy ($) | 57.66 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AJER JEFFREY ROBERT | Director | 23 Sep 2026 | Acquired (+) | 2,000 | 57.66 | 115,320 |
| BRAINARD DIANA | Director | 23 Sep 2026 | Acquired (+) | 2,000 | 57.66 | 115,320 |
| CHESS ROBERT | Director | 23 Sep 2026 | Acquired (+) | 2,000 | 57.66 | 115,320 |
| GREER R SCOTT | Director | 23 Sep 2026 | Acquired (+) | 2,000 | 57.66 | 115,320 |
| WHITFIELD ROY A | Director | 23 Sep 2026 | Acquired (+) | 2,000 | 57.66 | 115,320 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |